Acomplia Introduction Arlington Heights IL

As the introduction of this drug is new the success of this drug remains to be seen. But the real problem is the availability of the drug. At present only a few numbers of pharmacies are keeping it with them as FDA has not approved its use as a weight loss pill. Till the moment when FDA approves the drug, the pharmacies in US would be having tough time assuring the customers of its arrival soon.

The clinical results of Acomplia (Rimonabant) for 2 years showed much promise for this new weight loss drug. In the clinical trials around 40% of the sample lost 10% or more weight as a result of taking the drug. Apart from that the cardiovascular and metabolic risk factors related to obesity are minimised. These all are leading to a wide spread notion that Acomplia would help an obese person get slimmer when taken. The initial results of the effects of Acomplia from EU and UK is satisfactory to Sanofi-Aventis standards. But the success stories which are remaining to be unfolded from UK and EU where it has been launched last month, would only state whether this diet pill Acomplia would stand the test of time.

Howsoever successful the effects of Acomplia may be as a weight loss pill there certainly would be some side effects like nausea, dizziness, insomnia and stomach upset etc. which a user might have to deal with. But the side effects have much lower intensity than other similar diet pills. The pill must be taken with consultation of a doctor to get its maximum effect on weight loss. A person with heart disease, blood pressure, diabetes, allergy and hypertension should tell a doctor first before going for the drug. Children, pregnant woman and breast feeding mothers too should consult doctor if they are to take the pill.

Acomplia (Rimonabant) is the latest weight loss drug developed by French pharmaceutical major Sanofi-Aventis. It has been introduced in UK and EU market and is pending FDA approval for sale in US. As the drug is new the result of its effect remains to be seen.

About the Author:

Article Source:

thePhantomWriters Article Submission Service